Mabvax Therapeutics Holdings Inc

Find more results for NASDAQ:TELK

Officers and directors

Michael M. Wick M.D., Ph.D.
Chairman of the Board
J. David Hansen
President, Chief Executive Officer, Director
Gregory P. Hanson
Chief Financial Officer
Wendy K. Wee
Principal Accounting Officer, Vice President - Finance, Controller
Philip O. Livingston M.D.
Chief Science Officer, Director
William P. Kaplan Esq.
Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Wolfgang W. Scholz Ph.D.
Vice President - Antibody Discovery
Steven R. Schow Ph.D.
Vice President - Research
Kenneth M. Cohen
Robert E. Hoffman


11588 Sorrento Valley Rd Ste 20
SAN DIEGO, CA 92121-1336
United States - Map
+1-858-2599405 (Phone)

Website links

MabVax Therapeutics Holdings, Inc., formerly Telik, Inc. (Telik), is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In July 2014, Telik Inc announced that MabVax Therapeutics merged with a wholly owned subsidiary of Telik Inc and became a wholly owned subsidiary of Telik Inc.

Related companies

* Delayed by up to 20 minutes -  Disclaimer